novan
receives
approval
transfer
nasdaq
capital
market
trading
nasdaq
capital
market
expected
begin
november
company
receives
additional
grace
period
may
satisfy
bid
price
requirement
maintain
nasdaq
listing
morrisville
globe
newswire
novan
company
novan
nasdaq
novn
today
announced
november
listing
qualifications
department
nasdaq
stock
market
llc
nasdaq
approved
company
request
transfer
listing
nasdaq
capital
market
nasdaq
global
market
transfer
expected
take
effect
start
trading
thursday
november
approval
part
based
upon
company
meeting
applicable
market
value
publicly
held
shares
requirement
continued
listing
applicable
requirements
initial
listing
nasdaq
capital
market
except
minimum
bid
price
requirement
company
written
notice
intention
cure
minimum
bid
price
deficiency
effecting
reverse
stock
split
necessary
agreement
conditions
outlined
nasdaq
listing
agreement
additional
supporting
information
provided
company
application
transfer
company
listing
nasdaq
capital
market
expected
impact
trading
company
shares
company
shares
continue
trade
uninterrupted
symbol
nasdaq
capital
market
continuous
trading
market
operates
substantially
manner
nasdaq
global
market
listed
companies
must
meet
certain
financial
corporate
governance
requirements
qualify
continued
listing
transfer
nasdaq
capital
market
nasdaq
granted
company
second
grace
period
calendar
days
may
regain
compliance
minimum
bid
price
requirement
continued
listing
regain
compliance
closing
bid
price
company
common
stock
must
meet
exceed
per
share
minimum
consecutive
business
days
prior
may
company
intends
continue
actively
monitor
minimum
bid
price
requirement
appropriate
consider
available
options
resolve
deficiencies
regain
compliance
novan
novan
clinical
biotechnology
company
focused
leveraging
proprietary
nitric
oxide
based
technology
platform
generate
macromolecular
new
chemical
entities
nces
treat
multiple
indications
dermatology
men
women
health
infectious
diseases
gastroenterology
conditions
significant
unmet
needs
company
lead
product
candidate
topical
antiviral
gel
treatment
molluscum
contagiosum
currently
evaluated
pivotal
phase
clinical
study
company
believes
topical
therapy
rapid
treatment
benefit
approved
would
address
important
need
treatment
molluscum
statements
statements
contained
press
release
describe
historical
facts
may
constitute
statements
term
defined
private
securities
litigation
reform
act
statements
may
identified
words
believe
expect
may
plan
potential
similar
expressions
based
company
current
beliefs
expectations
statements
include
limited
statements
related
potential
therapeutic
value
company
platform
technology
company
plans
regain
compliance
nasdaq
listing
standards
statements
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
company
expectations
including
limited
risks
uncertainties
company
ongoing
future
product
development
activities
preclinical
studies
may
prove
successful
demonstrating
concept
may
show
adverse
toxicological
findings
even
successful
may
necessarily
predict
subsequent
clinical
trials
show
requisite
safety
efficacy
company
product
candidates
company
ability
enter
arrangements
third
parties
support
development
efforts
terms
acceptable
company
risks
uncertainties
clinical
development
process
including
among
others
length
expense
ability
enroll
patients
reliance
third
parties
potential
delays
impacts
whether
result
pandemic
factors
results
earlier
research
preclinical
clinical
trials
may
predictive
results
conclusions
interpretations
later
research
activities
additional
trials
risks
related
regulatory
approval
process
lengthy
inherently
unpredictable
including
risk
company
product
candidates
may
approved
additional
studies
may
required
approval
delays
may
occur
company
ability
obtain
additional
funding
enter
strategic
business
relationships
necessary
useful
development
company
product
candidates
risks
related
manufacture
raw
materials
including
company
active
pharmaceutical
ingredient
drug
product
components
utilized
clinical
trial
materials
including
failure
transfer
technology
processes
third
parties
effectively
failure
third
parties
obtain
approval
maintain
compliance
fda
comparable
regulatory
authorities
operational
disruptions
result
pandemic
including
delays
disruptions
enrollment
conduct
phase
trial
risks
uncertainties
described
company
annual
report
filed
sec
form
twelve
months
ended
december
amended
company
subsequent
filings
sec
statements
speak
date
press
release
novan
disclaims
intent
obligation
update
statements
reflect
events
circumstances
date
statements
except
may
required
law
investor
media
contact
jenene
thomas
jtc
team
llc
novn
